Market Research Logo

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

222 Reports from BioSeeker Group AB

   
  • Target Atlas in Head and Neck Cancer: A Competitive Outlook

    ... cancer by identifying the most promising Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Head and Neck Cancer: A Competitive ... Read More

  • Target Atlas in Leukemia: A Competitive Outlook

    ... development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Leukemia: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline ... Read More

  • Target Atlas in Lymphoma: A Competitive Outlook

    ... development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Lymphoma: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline ... Read More

  • Target Atlas in Melanoma: A Competitive Outlook

    ... development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Melanoma: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline ... Read More

  • Target Atlas in Myeloma: A Competitive Outlook

    ... development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Myeloma: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline ... Read More

  • Target Atlas in Nasopharyngeal Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Nasopharyngeal Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Oesophageal Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Oesophageal Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Peritoneal Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Peritoneal Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Renal Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Renal Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Thyroid Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Thyroid Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Myelodysplastic Syndrome: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Myelodysplastic Syndrome: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Fallopian Tube Cancer: A Competitive Outlook

    ... the most promising Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Fallopian Tube Cancer: A Competitive Outlook" is a one-of-a-kind, ... Read More

  • Target Atlas in Pancreatic Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Pancreatic Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Target Atlas in Lung Cancer: A Competitive Outlook

    ... Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed. "Target Atlas in Lung Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, ... Read More

  • Protein Kinase Inhibitors Drug Pathway Analyzer

    ... tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 287 drug targets that are included in this drug-pathway analyzing tool. No less than 280 of these ... Read More

  • Breast Cancer Drug Pipeline Update

    ... metastatic setting, the overall survival remains below five years. There are today 636 companies plus partners developing 706 drugs targeting breast cancer in development. In addition, there are 7 suspended drugs and the accumulated number ... Read More

  • Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    ... and organ morphogenesis and in the maintenance of cell and tissue structure and function. There are today 67 companies plus partners developing 50 targeting ECM-receptor interaction drugs in 121 developmental projects in cancer. In addition, ... Read More

  • GnRH Signaling Pathway in Oncology Drug Pipeline Update

    ... FSH. There are today 185 companies plus partners developing 234 GnRH signaling pathway targeting drugs in 844 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs ... Read More

  • Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update

    ... development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. There are today 341 companies plus partners ... Read More

  • Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update

    ... addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 178 drugs. Modulators Of The Actin Cytoskeleton For The Treatment Of Cancer Drug Pipeline Update ... Read More

  • Angiogenesis in Oncology Drug Pipeline Update

    ... of ceased drugs over the last years amount to another 218 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are ... Read More

  • Protein Kinase Inhibitors in Oncology Drug Pipeline Update

    ... successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there ... Read More

  • Immunotherapy in Oncology Drug Pipeline Update

    ... antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 830 companies plus partners developing 1578 cancer immunotherapy drugs in 4062 developmental projects in cancer. In addition, there are 19 suspended ... Read More

  • Hematological Cancers Drug Pipeline Update

    ... hematological cancer drugs in 2542 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 308 drugs. Hematological Cancers Drug ... Read More

  • Melanoma Drug Pipeline Update

    ... five-year survival of advanced patients remains below 20%. There are today 374 companies plus partners developing 403 drugs targeting melanoma in development. In addition, there are 2 suspended drugs and the accumulated number of ceased ... Read More

1 2 3 5 7 8 9

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook